NCT01105533 - A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

October 31, 2010

Study Completion Date

September 30, 2011

Conditions

Neoplasm

Interventions

DRUG

PF-00337210

0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous

DRUG

PF-00337210

1mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

2mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

4mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

6mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

9mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

8mg Capsule Once Daily (Dose Escalation) Continuous

DRUG

PF-00337210

4mg Capsule Twice Daily (Dose Escalation) Continuous

DRUG

PF-00337210

6mg Capsule Twice Daily (Dose Escalation) Continuous

DRUG

PF-00337210

6mg Capsule Twice Daily (Dose Expansion) Continuous

Trial Locations (3)

48201

Pfizer Investigational Site, Detroit

48202

Pfizer Investigational Site, Detroit

53792

Pfizer Investigational Site, Madison